Posters

      Nicotine Pharmacokinetics and Pharmacodynamic Effects of P4M3 Compared with Subjects’ Own Electronic Cigarette

      Fredersdorf, S.; Dobrynina, M.; Taranu, B.; Teichert, A.; Ancerewicz, J. Ancerewicz.; Haziza, C.; Lüdicke, F.
      Conference date
      Feb 22, 2019
      Conference name

      Society for Research on Nicotine and Tobacco (SRNT) 2019
      Link to more information
      Topic
      Summary

      Background: P4M3 is an e-cigarette developed as an alternative product for smokers with the potential to reduce the risk of smoking-related diseases. This study investigated the nicotine pharmacokinetic (PK) and pharmacodynamic (PD) effects of four P4M3 variants compared with subjects’ own e-cigarette. Methods: This was a single-center, open-label, concentration-ranging study to evaluate the nicotine PK profile and PD effects (puffing topography, craving and sensory assessment, product evaluation) in healthy adult users of e-cigarettes and using P4M3 (1.7%, 3%, or 4% e-liquid nicotine concentration) or their own e-cigarette (mean e-liquid nicotine concentration 3%). Subjects used all products with a fixed puffing regimen (12 puffs) and ad libitum for 60 minutes. Fifteen subjects were randomized to one of two sequences to cross-over the use of P4M3-1.7% variants. The study was registered at www.clinicaltrials.gov (NCT03379740). Results: Following the fixed puffing regimen, there was a nicotine concentration-dependent increase in mean maximum nicotine concentrations (Cmax) for P4M3 variants from 5.1 to 12.0 ng/ml, while mean Cmax for subjects’ own e-cigarette was 5.4 ng/ml. Median time to Cmax was 7–10 minutes for all products. Nicotine exposure, assessed as area under the curve over four hours (AUC0- 4h), for P4M3 variants increased for higher nicotine concentrations from 7.0 to 13.6 h×ng/mL, while mean AUC0-4h for subjects’ own e-cigarette was 7.8 ng/ml. Craving reduction and mean puff volume were comparable for all products. Following ad libitum use, there was a nicotine concentration-dependent increase in mean AUC0-4h for P4M3 variants from 28.6 to 52.8 h×ng/mL, while mean AUC0-4h for subjects’ own e-cigarette was 33.8 h×ng/mL. Product evaluation subscale scores were higher for subjects’ own e-cigarette. Mean total puff volume was 2050 mL for subject’s own e-cigarette and 1930 mL for P4M3-4% but higher for other P4M3 variants, ranging from 2600–2950 mL. Conclusions: Nicotine exposure increased with increasing nicotine concentrations of P4M3 variants and was comparable to or exceeding subject’s own e-cigarette. There were no safety signals observed.

      Related Publications

      Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

      Clinical

      Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in Japan: A comparison with continued cigarette use or smoking abstinence

      Clinical

      Reduced Exposure To Harmful And Potentially Harmful Constituents after 90 Days Of Use Of Tobacco Heating System 2.2 Menthol In Japan: A Comparison With Continued Cigarette Use Or Smoking Abstinence

      Clinical

      Psychometric Evaluation of the mCEQ applied to Cigarettes and Heat-Not-Burn Products in the US and Japan

      Clinical

      Pharmacokinetics Of Nicotine And Subjective Effects Following The Single Use Of A Non-Menthol And Menthol Version Of Tobacco Heating System 2.2 In Two Studies In Japan: A Comparison With Single Use Of A Combustible Cigarette And Nicotine Gum

      Clinical

      Pharmacokinetics of Nicotine and Subjective Effects Following the Single Use of a Non-Menthol and Menthol Version of Tobacco Heating System 2.2 in Two Studies in Japan: A Comparison with Single Use of a Combustible Cigarette and Nicotine Gum

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.